RNA interference - About the reality to be exploited in cancer therapy

Methods and Findings in Experimental and Clinical Pharmacology

Volumn 29, Issue 6, 2007, Pages 417-421

  Bakalova, Rumiana ^a,b  

^a NATIONAL INSTITUTE OF RADIOLOGICAL SCIENCES   (Japan)

^b NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

Author keywords

Bcr abl positive cells; Glivec; Leukemia; RNA interference

Indexed keywords

BCR ABL PROTEIN; DOUBLE STRANDED RNA; HYBRID PROTEIN; IMATINIB; SMALL INTERFERING RNA;

ARTICLE; CANCER GENE THERAPY; CANCER THERAPY; CELL IMMORTALIZATION; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DNA MICROARRAY; GENE EXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; LONG TERM CARE; MAMMAL CELL; NUCLEOTIDE SEQUENCE; ONCOGENE; RNA INTERFERENCE;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIVISION; CELL SURVIVAL; FUSION PROTEINS, BCR-ABL; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMANS; K562 CELLS; LYMPHOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ONCOGENES; PIPERAZINES; PYRIMIDINES; RNA INTERFERENCE; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 35349006389     PISSN: 03790355     EISSN: None     Source Type: Journal    
DOI: 10.1358/mf.2007.29.6.1119167     Document Type: Article

References (42)

1. Elbashir, S.M., Harborth, J., Lendeckel, W., Yalcin, A., Weber, K., Tuschl, T. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 2001, 411: 494-8.
2. Fire, A., Xu, S., Montgomery, M.K., Kostas, S.A., Driver, S.E., Mello, C.C. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998, 391: 806-11.
3. Song, E., Lee, S.K., Wang, J. et al. RNA interference targeting Fas protects mice from fulminant hepatitis. Cell 2003, 101: 25-33.
4. Zamore, P.D., Tuschl, T., Sharp, P.A., Battel, D.P. RNAi: Double-stranded RNA directs the ATP-dependent cleavage of mRNA at 21 to 23 nucleotide intervals. Cell 2000, 101: 25-33.
5. Bernstein, E., Caudy, A.A., Hammond, S.M., Hannon, G.J. Role of bidentate ribonuclease in the inhibition step of RNA interference. Nature 2001, 409: 363-6.
6. Martinez, J., Patkaniowska, A., Urlaub, H., Luhrmann, R., Tuschl, T. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi. Cell 2002, 110: 563-74.
7. Ui-Tei, K., Zenno, S., Miyata, Y., Saigo, K. Sensitive assay of RNA interference in Drosophila and Chinese hamster cultured cells using firefly luciferase gene as target. FEBS Lett 2000, 479: 79-82.
8. Elbashir, S.M., Martinez, J., Patkaniowska, A., Lendeckel, W., Tuschl, T. Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J 2001, 20: 6877-88.
9. Zhelev, Z., Bakalova, R., Ohba, H. et al. Suppression of bcr-abl synthesis by siRNAs or tyrosine kinase activity by Glivec alters different oncogenes, apoptotic/antiapoptotic genes and cell proliferation factors (a microarray study). FEBS Lett 2004, 570: 195-204.
10. Ohba, H., Zhelev, Z., Bakalova, R. et al. Inhibition of bcr-abl and/ or c-abl gene expression by small interfering double-stranded RNAs: Cross-talk with cell proliferation factors and other oncogenes. Cancer 2004, 101: 1390-1403.
11. Elbashir, S.M., Lendeckel, W., Tuschl, T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001, 15: 188-200.
12. Manoharan, M. RNA interference and chemically modified small interfering RNAs. Curr Opin Chem Biol 2004, 8: 570-90.
13. Chiu, Y.L., Rana, T.M. siRNA function in RNAi: A chemical modification analysis. RNA 2003, 9: 1034-48.
14. Grunweller, A., Wyszko, E., Bieber, B., Jahnel, R., Erdmann, V.A., Kurreck, J. Comparison of different antisense strategies in mammalian cells using locked nucleic acids, 2′-O-methyl RNA, phosphorothioates and small interfering RNA. Nucleic Acids Res 2003, 31: 3185-93.
15. Braasch, D.A., Jensen, S., Liu, Y. et al. RNA interference in mammalian cells by chemically modified RNA. Biochemistry 2003, 42: 7967-75.
16. Amarzguioui, M., Holen, T., Babaie, E., Prydz, H. Tolerance for mutations and chemical modifications in a siRNA. Nucleic Acids Res 2003, 31: 589-95.
17. Braasch, D.A., Paroo, Z., Constantinescu, A. et al. Biodistribution of phosphodiester and phosphorothioate siRNA. Bioorg Med Chem Lett 2004, 14: 1139-43.
18. Chiu, Y.L., Rana, T.M. RNAi in human cells: Basic structural and functional features of small interfering RNA. Mol Cell 2002, 10: 549-61.
19. Czauderna, F., Fechtner, M., Dames, S. et al. Structural variations and stabilizing modifications of synthetic siRNAs in mammalian cells. Nucleic Acids Res 2003, 31: 2705-16.
20. a directed to enhance intracellular gene silencing. J Am Chem Soc 2004, 126: 13612-13.
21. Oishi, M., Nagasaki, Y., Itaka, K., Nishiyama, N., Kataoka, K. Lactosylated poly(ethylene glycol)-siRNA conjugate through acid-labile beta-thiopropionate linkage to construct pH-sensitive polyion complex micelles achieving gene silencing in hepatoma cells. J Am Chem Soc 2005, 127: 1624-5.
22. Kam, N.W., Liu, Z., Dai, H. Functionalization of carbon nanotubes via cleavable disulfide bonds for efficient intracellular delivery of siRNA and potent gene silencing. J Am Chem Soc 2005, 127: 12492-3.
23. Lorenz, C., Hadwiger, P., John, M., Vomlocher, H.P., Unverzagt, C. Steroid and lipid conjugates of siRNAs to enhance cellular uptake and gene silencing in liver cells. Bioorg Med Chem Lett 2004, 14: 4875-7.
24. Chiu, Y.L., Ali, A., Chu, C.Y., Cao, H., Rana, T.M. Visualizing a correlation between siRNA localization, cellular uptake, and RNAi in living cells. Chem Biol 2004, 11: 1165-75.
25. Muratovska, A., Eccles, M.R. Conjugate for efficient delivery of short interfering RNA (siRNA) into mammalian cells. FEBS Lett 2004, 558: 63-8.
26. Kubo, T., Zhelev, Z., Bakalova, R., Ohba, H., Doi, K., Fujii, M. Controlled intracellular localization and enhanced antisense effect of oligonucleotides by chemical conjugation. Org Biomol Chem 2005, 21: 3257-9.
27. Kubo, T., Takamori, K., Kanno, K. et al. Efficient cleavage of RNA, enhanced cellular uptake, and controlled intracellular localization of conjugate DNAzymes. Bioorg Med Chem Lett 2005, 15: 167-70.
28. Kubo, T., Morikawa, M., Ohba, H., Fujii, M. Synthesis of DNA-peptide conjugates by solid-phase fragment condensation. Org Lett 2003, 5: 2623-6.
29. Kubo, T., Bakalova, R., Ohba, H., Fujii, M. Antisense effects of DNA-peptide conjugates. Nucleic Acids Res Suppl 2003, 3: 179-80.
30. Kubo, T., Takamori, K., Bakalova, R., Ohba, H., Fujii, M. Conjugated DNA-enzymes. Nucleic Acids Res Suppl 2003, 3: 177-8.
31. Zhang, Y.M., Tung, C.H., He, J. et al. Construction of a novel chimera consisting of a chelator-containing Tat peptide conjugated to a morpholino antisense oligomer for technetium-99m labeling and accelerating cellular kinetics. Nucleic Med Biol 2006, 33: 263-9.
32. Juliano, R.L. Peptide-oligonucleotide conjugates for the delivery of antisense and siRNA. Curr Opin Mol Ther 2005, 7: 132-6.
33. Hall, A.H., Wan, J., Spesock, A., Sergueeva, Z., Shaw, B.R., Alexander, K.A. High potency silencing by single-stranded boranophosphate siRNA. Nucleic Acids Res 2006, 34: 2773-81.
34. Allerson, C.R., Sioufi, N., Jarres, R. et al. Fully 2′-modified oligonucleotide duplexes with improved in vitro potency and stability compared to unmodified small interfering RNA. J Med Chem 2005, 48: 901-4.
35. Kraynack, B.A., Baker, B.F. Small interfering RNAs containing full 2′-O-methylribonucleotide-modified sense strands display Argonaute-2/eIF2C2-dependent activity. RNA 2006, 12: 163-76.
36. Morrissey, D.V., Lockridge, J.A., Shaw, L. et al. Potent and persistent in vivo anti-HBV activity of chemically modified siRNAs. Nat Biotechnol 2005, 23: 1002-7.
37. Soutschek, J., Akinc, A., Bramlage, B. et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004, 432: 173-8.
38. Kim, D.H., Behlke, M.A., Rose, S.D., Chang, M.S., Choi, S., Rossi, J.J. Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy. Nat Biotechnol 2005, 23: 222-6.
39. Rose, S.D., Kim, D.H., Amarzguioui, M. et al. Functional polarity is introduced by Dicer processing of short substrate RNAs. Nucleic Acids Res 2005, 33: 4140-56.
40. Amarzguioui, M., Rossi, J.J., Kim, D. Approaches for chemically synthesized siRNA and vector-mediated RNAi. FEBS Lett 2005, 579: 5974-81.
41. Wohlbold, L., Van Der Kuip, H., Miething, C. et al. Inhibition of bcr-abl gene expression by small interfering RNA sensitizes for imatinib mesylate (STI571). Blood 2003, 102: 2236-39.
42. Wu, H., Heit, W.N., Yang, J.M. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003, 63: 1515-19.